Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Small-cap biotech companies can deliver outsized returns over the long run if they develop breakthrough medicines that go on to generate massive sales. However, some of these smaller drugmakers aren't ...

Recursion Pharmaceuticals has an exciting approach to developing therapies. The company recently reported positive phase 2 results for one of its products. While this small biotech looks promising, it ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage ...

Amid fierce debate about prescription-drug prices and countless proposals to rein them in, there has been a point of widespread agreement: Those prices at least partly reflect the vast amount of time, ...

Recursion Pharmaceuticals (NASDAQ: RXRX), a biotech focused on artificial intelligence (AI), became a publicly traded company in 2021 -- a time when AI did not grab nearly as much attention (if any at ...

In recent days, Recursion Pharmaceuticals attracted heightened attention as traders responded to the stock’s very large short interest, alongside the announcement of a $12.5 million milestone payment ...